Trial Profile

A Multicenter, Open-Labeled, Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of Intravitreal AG-73305 in Patients With Diabetic Macular Edema

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AG 73305 (Primary)
Indications Diabetic macular oedema
Focus Adverse reactions
Sponsors Allgenesis Biotherapeutics

Most Recent Events

15 Apr 2024 The protocol has been amended to increase in A single IVT dose for cohort 4 from 3 mg to 4 mg.
15 Apr 2024 Status changed from recruiting to active, no longer recruiting.
08 Nov 2023 According to Allgenesis Biotherapeutics media release preliminary data from the trial were presented at the 2023 American Academy of Ophthalmology (AAO) conference.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com